Anti-VEGF Options and Questions for Diabetic Eye Disease Treatment

In 2010, the Diabetic Retinopathy Clinical Research (DRCR) Network published the first phase 3 results showing the benefits of intravitreal anti–vascular endothelial growth factor (VEGF) injections for diabetic macular edema (DME). Over the next decade and a half, the landscape of anti-VEGF injections has exploded as more options have become available for DME treatment, including multiple anti-VEGF agents, combination anti-VEGF and angiopoietin-2 inhibitors, high-dose anti-VEGF options, biosimilars, and now an alternate delivery method providing continuous anti-VEGF delivery. The Continuous Ranibizumab Delivery via Port Delivery System vs Monthly Ranibizumab for Treatment of Diabetic Macular Edema (Pagoda) and Port Delivery System With Ranibizumab vs Monitoring in Nonproliferative Diabetic Retinopathy Without Macular Edema (Pavillion) randomized clinical trials report results on the port delivery system (PDS) with ranibizumab, demonstrating beneficial effects in both DME treatment and Diabetic Retinopathy Severity Scale (DRSS) score improvement. Although more options are great for patients and health care professionals, determining which DME treatment approach to follow is complex and based on a multitude of factors.

This post was originally published on this site